CodeBreak 100: results show durability of clinical benefit with sotorasib in patients with non-small cell lung cancer

Durability of clinical benefit and biomarkers in patients with advanced non-small cell lung cancer (NSCLC)
ESMO HIGHLIGHTS, Genitourinary

SPARTAN: quality of life related to the use of apalutamide in patients with castration-resistant non-metastatic prostate cancer

There were no therapeutic options specifically approved for the population of patients with non-metastatic castration-resistant
ESMO HIGHLIGHTS, Gynecological Cancer

Study assesses benefit of erdafitinib in patients with advanced urothelial carcinoma and FGFR mutation

Study results BLC2001 (757P – An observational study of outcomes of patients (pts) with advanced

Olaparib stands out as a treatment option in patients with castration-resistant metastatic prostate cancer

See the results of the PROfound trial presented at ESMO Virtual Congress 2020, whose updates

ESMO 2020: Impact of new studies in the treatment of lung cancer

Three main clinical trials for EGFR mutation non-small cell lung carcinoma presented at ESMO Virtual
ESMO News, Gynecological Cancer

5-year follow-up data from the SOLO-1 trial with analysis of the information up to March 5, 2020 were highlighted at ESMO 2020

The efficacy of olaparib as maintenance therapy in newly diagnosed advanced ovarian cancer with BRCA

Study suggests correlation between the use of vitamin D in the pretreatment and decreased risk of immune checkpoint inhibitor‐induced colitis

Immune checkpoint inhibitors can cause serious immune-related adverse events A study released in June of
Prostate Cancer

PREMISE assesses the efficacy and safety of enzalutamide in patients with mCRPC in a real-world setting

Enzalutamide may offer more benefits to patients with mCRPC who have not been previously exposed
Prostate Cancer

Real-world data demonstrates effective pain control after using enzalutamide in patients with prostate cancer

PREMISE trial also evaluated pain control in patients with metastatic castration-resistant prostate cancer Randomized clinical
Lung cancer

New recommendation published on screening for lung cancer in people who do not show signs or symptoms

Such changes are expected to double the number of people in the United States eligible
skin cancer

Damage to spermatogenesis may be associated with immunotherapy, study suggests

Establishing the association of immunotherapy with spermatogenesis is an essential step for the preservation of
GI Cancer

Study evaluates degree of response associated with chemotherapy with FOLFIRINOX or Gemcitabine plus Nab-Paclitaxel in the first line in the treatment of resectable pancreatic adenocarcinoma

FOLFIRINOX and Gemcitabine plus Nab-Paclitaxel are first-line chemotherapy regimens for pancreatic cancer, but their relative
Lung cancer

Pyrotinib induces anti-tumor activity in non-small cell lung cancer with HER2 mutation

Non-small cell lung cancer (NSCLC) patients with HER2 mutation are between 1% and 4% of

COVID – 19 and the factors that influence clinical outcomes in patients with cancer

A study recently published in The Lancet sought to understand the course of COVID-19 and
AACR 2020, skin cancer

Real-world analysis of nivolumab dosing regimens show that duration of therapy and adverse effects are similar for doses every 2 or 4 weeks

The analysis was performed in an oncology setting of the American community Real-world results of